Loading
A phase 2 trial of Durvalumab, Carboplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by Innate Pharma, now recruiting.
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) is a phase 2 interventional study registered as NCT05742607 by Innate Pharma, with 70 participants planned, started 2023-06-23 and due to reach its primary completion in 2027-06. Interventions recorded: IPH5201 + durvalumab + standard chemotherapy. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/